Seat­tle Ge­net­ics gets an­oth­er drug close to the fin­ish line

Seat­tle Ge­net­ics’ pro­duc­tive streak con­tin­ues.

Af­ter clos­ing out 2019 with its sec­ond ap­proved drug  – a po­ten­tial block­buster in Pad­cev  – the ADC biotech then pre­sent­ed da­ta show­ing that Pad­cev com­bined with Keytru­da may be more ef­fec­tive than Keytru­da alone for blad­der can­cer pa­tients.

And on Thurs­day, the com­pa­ny an­nounced an­oth­er drug has been ac­cept­ed for FDA re­view and has been giv­en pri­or­i­ty sta­tus. The drug, tu­ca­tinib,  is be­ing as­sessed as part of a com­bi­na­tion treat­ment for lo­cal­ly ad­vanced or metasta­t­ic HER2-pos­i­tive breast can­cer. A PDU­FA date has been set for Au­gust 20, 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.